Consolidation therapies for acute myeloid leukemia in the first complete remission: chemotherapy or transplantation? / 白血病·淋巴瘤

ABSTRACT

Acute myeloid leukemia is a heterogeneous disease, and it is categorized as favorite-, intermediate- and poor-risk groups based on the cytogenetics and molecular markers. The strategies for consolidation therapies are different among the three risk groups. In the intermediate-risk group, patients can receive chemotherapy, autologous stem cell transplantation, and allogeneic hematopoietic stem cell transplantation. Many studies had observed the value of allogeneic hematopoietic stem cell transplantation as the consolidation therapy in adults and children with intermediate-risk AML. Recently, the transplant technique is developing rapidly, particularly in the area of alternative donor transplantation, and haploidentical related donor transplantation is the most important choice for those without sibling identical donors.